CAESAREA, Israel--(BUSINESS WIRE)--
LabStyle Innovations Corp. (OTCQB:DRIO), developer of Dario™,
a cloud-based, mobile health platform for diabetes and blood glucose
monitoring, announced today that company president and chief executive
officer Mr. Erez Raphael will present at the Biotech Showcase 2014 on
Monday, January 13, 2014 at 8:30 a.m., 55 Cyril Magnin Street, San
Francisco, Level 4, Cyril Magnin Foyer. Mr. Raphael will address
participants on the topic: "LabStyle Innovations Corp. (OTCQB:DRIO)
End-to-End Smart Solutions for Diabetes in a Mobile Age." He will also
give a hands-on demonstration of the Dario™ software and
related blood glucose monitoring system and be available to answer
"I am very much looking forward to presenting at the Biotech Showcase
and to meeting everyone. During my presentation, I plan to review our
progress to date, our current status and our plans for the coming year,"
said Mr. Raphael. "We believe that the right mobile health platform for
diabetes and blood glucose monitoring can transform the quality of
diabetes care. I will explain why Dario™ is a game changer
and demonstrate how it will empower people with diabetes to take charge
of their health with the right tools, insights, and support, right in
The audio portion of Mr. Raphael's presentation will be available live
at the following link.
A playback of the audio portion of the presentation will be available
for thirty days following at the same link.
The slide presentation will be available at this link.
The complete Dario™ diabetes management platform combines an
all-in-one, blood glucose monitoring system, a smart phone application
(iOS & Android), and a website application.
LabStyle's world roll-out of the Dario™ diabetes management
platform began on December 12th with the market launch of the
Dario™ iOS app in the United Kingdom, Australia and New
Zealand. The Dario™ iOS app is now available in these
countries for free download at the Apple app store. LabStyle remains on
course to launch the Dario™iOS app
in Italy and Belgiumand the Dario™Android
app, in the United Kingdom, New Zealand, Australia, Italy and
Belgium - both during first quarter 2014. Plans are also on track to
soft launch the Dario™ all-in-one blood glucose monitoring
system in the United Kingdom and in Italy during first quarter 2014.
LabStyle filed a Premarket Notification Application, also known as a
510(k), with the US Food and Drug Administration (FDA) for the Dario™
Blood Glucose Monitoring System at the close of 2013.
About LabStyle Innovations
LabStyle Innovations Corp. (OTCQB:DRIO) is a mobile health (mHealth)
company developing and commercializing patent-pending technology
providing consumers with laboratory-testing capabilities using smart
phones. LabStyle's flagship product, Dario™, is a mobile, cloud-based,
diabetes management platform which includes an ‘all-in-one',
pocket-sized, blood glucose monitoring system, iOS and Android apps and
a web application. Dario™ received CE mark certification in September
2013 and began its world rollout in select countries in December 2013.
LabStyle is pursuing patent applications in multiple areas covering the
specific processes related to blood glucose level measurement as well as
more general methods of rapid tests of body fluids using mobile devices
and cloud-based services. For more information: www.mydario.com
Cautionary Note Regarding Forward-Looking Statements
This news release, the presentation referred to herein and the
statements of representatives and partners of LabStyle Innovations Corp.
(the "Company") related thereto contains or may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Statements that are not statements of historical
fact may be deemed to be forward-looking statements. Without limiting
the generality of the foregoing, words such as "plan," "project,"
"potential," "seek," "may," "will," "expect," "believe," "anticipate,"
"intend," "could," "estimate" or "continue" are intended to identify
forward-looking statements. Readers are cautioned that certain important
factors may affect the Company's actual results and could cause such
results to differ materially from any forward-looking statements that
may be made in this news release. Factors that may affect the Company's
results include, but are not limited to, regulatory approvals, product
demand, market acceptance, impact of competitive products and prices,
product development, commercialization or technological difficulties,
the success or failure of negotiations and trade, legal, social and
economic risks, and the risks associated with the adequacy of existing
cash resources. Additional factors that could cause or contribute to
differences between the Company's actual results and forward-looking
statements include, but are not limited to, those risks discussed in the
Company's filings with the U.S. Securities and Exchange Commission.
Readers are cautioned that actual results (including, without
limitation, the timing for and results of FDA review of Dario™,
the Company's anticipations of the functionality of Dario™,
and the results of the Company's commercialization efforts for Dario™)
may differ significantly from those set forth in the forward-looking
statements. The Company undertakes no obligation to publicly update any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by applicable law.
Dario™ and the Dario™ logo are trademarks owned by LabStyle Innovation
© 2013 LabStyle Innovations Corp. All rights reserved.
Source: LabStyle Innovations Corp.